Physician profile
Elon Luzon
NPI 1700989845
$11,720.59
in general payments reported to CMS, 2019-2025
31 companies · $2,568 in 2025
The $2,568 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $682 · 2021: $1,299 · 2022: $1,316 · 2023: $2,287 · 2024: $2,091 · 2025: $2,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,169 · Travel and Lodging: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,169.43 |
| Travel and Lodging | $776.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,029.28 | 2019-2025 | Clareon, Centurion, Argos |
| Johnson & Johnson Vision Care, INC. | $1,090.87 | 2020-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $1,039.75 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $937.73 | 2022-2025 | Miebo, Xiidra, Infuse |
| Sun Pharmaceutical Industries INC. | $903.05 | 2019-2024 | Cequa |
| Abbvie INC. | $716.41 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $477.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $434.64 | 2019-2023 | |
| Allergan, INC. | $424.03 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $361.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $340.69 | 2021-2022 | |
| Harrow Eye, LLC | $286.07 | 2024-2025 | Vevye |
| New World Medical,INC. | $214.92 | 2022 | |
| Aerie Pharmaceuticals, INC. | $209.69 | 2019-2021 | |
| Shire North American Group INC | $185.87 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $185.15 | 2021-2025 | Tearcare System |
| Coopervision INC. | $125.92 | 2019-2025 | Myday Contact Lens |
| Thea Pharma INC. | $103.43 | 2025 | Iyuzeh |
| Optovue, INC. | $85.71 | 2020 | |
| Dompe US, INC. | $81.77 | 2024-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $75.63 | 2023 | Tecnis Simplicity, Tecnis Iol |
| Regeneron Healthcare Solutions, INC. | $74.21 | 2021-2024 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $56.60 | 2024-2025 | Izervay |
| Visionix USA, INC | $55.55 | 2022 | |
| Genentech USA, INC. | $49.25 | 2025 | Vabysmo |
| Ani Pharmaceuticals, INC. | $42.70 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $31.73 | 2021 | |
| Glaukos Corporation | $31.11 | 2025 | Istent Infinite, Idosetr |
| Apellis Pharmaceuticals, INC. | $30.23 | 2023 | Syfovre |
| Rxsight INC | $26.54 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elon Luzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.